Eight unnamed investors put $12.8 million into the Maple Grove, Minn.-based company, according to the July 13 filing. Amphora Medical launched the Series A round in May 2013, initially raising about $6 million, according to the Minneapolis/St. Paul Business Journal.
Baird Capital is a prior investor, according to Amphora Medical’s website.
Stealthy Amphora is running a 30-patient safety trial of its device, according to ClinicalTrials.gov. As of March, the company was still recruiting patients for the Cystoscopic Ablation Via RF Energy Clinical Trial study, dubbed CareTI. The primary endpoint is the rate of device-related complications through 12 weeks, with secondary endpoints of device technical success, procedural success and change from baseline of quality-of-life scores at 4 weeks, 12 weeks, 6 months and 12 months.
CareTI, launched in November 2014, is slated to close in October 2016, with an estimated primary completion date of October of this year, according to the clinical trial website.